Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2026

29 May - 2 Jun 2026

McCormick Place, Chicago, United States of America

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk...

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia...

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Velzatinib demonstrates broad activity across KIT mutations in advanced...

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston...

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type...

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Dr Luke Joseph Peppone - University of Rochester Medical Center, Rochester, USA

Bupropion shows benefit for cancer-related fatigue in cancer survivors ( Dr Luke Joseph Peppone - University of Rochester Medical Center, Rochester, USA )

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer ( Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada )

Aspirin in stage III colorectal cancer shows no significant DFS benefit but...

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )

Short-term fasting linked to improved chemo response in advanced ovarian cancer

Dr Claudia Marchetti - Policlinico Universitario Agostino Gemelli, Rome, Italy

Short-term fasting linked to improved chemo response in advanced ovarian cancer ( Dr Claudia Marchetti - Policlinico Universitario Agostino Gemelli, Rome, Italy )

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in...

Dr Nancy Y. Lee - Memorial Sloan Kettering, New York, USA

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in HPV-associated oropharyngeal cancer ( Dr Nancy Y. Lee - Memorial Sloan Kettering, New York, USA )

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

Amivantamab in HPV-unrelated mHNSCC gives high response rates after...

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness - Yale Cancer Center, New Haven, USA )

GLP-1 therapy associated with reduced breast cancer risk

Dr Elizabeth McDonald - University of Pennsylvania, Philadelphia, USA

GLP-1 therapy associated with reduced breast cancer risk ( Dr Elizabeth McDonald - University of Pennsylvania, Philadelphia, USA )

Structured exercise programme improves survival and reduces healthcare costs in...

Dr Kelvin K. Chan - Sunnybrook Odette Cancer Centre, Toronto, Canada

Structured exercise programme improves survival and reduces healthcare costs in colon cancer ( Dr Kelvin K. Chan - Sunnybrook Odette Cancer Centre, Toronto, Canada )

Gene expression test guided therapy in ER+/HER2- early breast cancer allows...

Dr Robert Stein - University College London, London, UK

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

Weight loss intervention improves quality of life in breast cancer survivors

Dr Jennifer Ligibel - Dana-Farber Cancer Institute, Boston, USA

Weight loss intervention improves quality of life in breast cancer survivors ( Dr Jennifer Ligibel - Dana-Farber Cancer Institute, Boston, USA )

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma ( Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA )

MCED blood test trial fails primary end point, but screening cut number of...

Dr Peter Sasieni - Queen Mary University of London, London, UK

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV ( Dr Peter Sasieni - Queen Mary University of London, London, UK )

Fedratinib improves spleen and symptom responses with promising survival...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

177Lu-rosopatamab plus standard of care shows manageable safety and favourable...

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )

GLP-1 use linked to improved survival in patients with cancer

Dr Jessica Paulus - Ontada, Boston, USA

GLP-1 use linked to improved survival in patients with cancer ( Dr Jessica Paulus - Ontada, Boston, USA )

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic...

Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma ( Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA )

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant...

Dr Vincent Chung - City of Hope, Duarte, USA

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer ( Dr Vincent Chung - City of Hope, Duarte, USA )

Early-onset gastrointestinal cancers show more advanced disease and wider...

Dr Jessica Paulus - Ontada, Boston, USA

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )

Xaluritamig plus abiraterone shows promising anti-tumour activity with...

Dr David Pook - Monash Health, Melbourne, Australia

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R...

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

Mobile app-based symptom monitoring helps maintain quality of life in advanced...

Prof Wendy Chan - The University of Hong Kong, Pok Fu Lam, Hong Kong

Mobile app-based symptom monitoring helps maintain quality of life in advanced cancer ( Prof Wendy Chan - The University of Hong Kong, Pok Fu Lam, Hong Kong )

Aspirin use linked to improved survival in endometrial cancer

Dr Zachary Gentry - The Ohio State University, Columbus, USA

Aspirin use linked to improved survival in endometrial cancer ( Dr Zachary Gentry - The Ohio State University, Columbus, USA )

miR371 shows promise as a surveillance biomarker for relapse in early-stage...

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Implanted tile-based radiation shows promise compared with stereotactic...

Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases ( Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA )

Daraxonrasib nearly doubles survival in previously treated metastatic...

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA

Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )

Yoga improves mood, fatigue, and insomnia in cancer survivors following...

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )

Lorlatinib delivers 7-year progression-free survival and durable brain control...

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer ( Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib shows benefit in dedifferentiated liposarcoma

Dr Mark Dickson - Memorial Sloan Kettering Cancer Center, New York, USA

Abemaciclib shows benefit in dedifferentiated liposarcoma ( Dr Mark Dickson - Memorial Sloan Kettering Cancer Center, New York, USA )

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer ( Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA )

Low-dose pembrolizumab plus chemotherapy improves survival and expands access...

Dr Nandini Menon - Tata Memorial Centre, Mumbai, India

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC ( Dr Nandini Menon - Tata Memorial Centre, Mumbai, India )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Darolutamide shows less cognitive decline than enzalutamide in advanced...

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in...

Dr Georg Lenz - University Hospital Münster, Münster, Germany

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas ( Dr Georg Lenz - University Hospital Münster, Münster, Germany )

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard...

Dr Hope Rugo - City of Hope, Duarte, USA

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer ( Dr Hope Rugo - City of Hope, Duarte, USA )

Omission of axillary lymph node dissection reduces arm morbidity without...

Dr Jana de Boniface - Capio St. Göran's Hospital, Stockholm, Sweden

Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases ( Dr Jana de Boniface - Capio St. Göran's Hospital, Stockholm, Sweden )

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable...

Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma ( Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China )

ASCO 2026: Breast cancer overview

Dr Hope Rugo - City of Hope, Duarte, USA

ASCO 2026: Breast cancer overview ( Dr Hope Rugo - City of Hope, Duarte, USA )

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment

Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment ( Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer